Reviva Pharmaceuticals Holdings, Inc. Reports Full Year 2022 Financial Results and Recent Business Highlights
30. März 2023 07:30 ET
|
Reviva Pharmaceuticals
- Topline data for pivotal Phase 3 trial evaluating brilaroxazine for the treatment of schizophrenia remains on track for mid-2023 – - Completed majority of non-clinical and clinical...
Reviva Pharmaceuticals to Present at the 35th Annual Roth Conference
07. März 2023 08:00 ET
|
Reviva Pharmaceuticals
CUPERTINO, Calif., March 07, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies...
Reviva Pharmaceuticals to Present at the 2023 BIO CEO and Investor Conference
31. Januar 2023 06:00 ET
|
Reviva Pharmaceuticals
Cupertino, Calif., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies...
Reviva Pharmaceuticals Announces Letter to Shareholders
04. Januar 2023 06:00 ET
|
Reviva Pharmaceuticals
CUPERTINO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies...
Reviva Pharmaceuticals Announces Positive Safety Data from Drug-Drug Interaction Clinical Study of Brilaroxazine
15. Dezember 2022 06:00 ET
|
Reviva Pharmaceuticals
- Topline data for pivotal Phase 3 RECOVER trial evaluating brilaroxazine for schizophrenia expected in mid-2023 - Brilaroxazine is a serotonin/dopamine modulator with a differentiated...
Reviva Pharmaceuticals Announces Canadian Composition of Matter Patent for Triple Reuptake Inhibitor RP1208
21. November 2022 06:00 ET
|
Reviva Pharmaceuticals
- RP1208 is in preclinical development for the potential treatment of depression and obesity – - Composition of matter patents for RP1208 have been granted in key markets around the world including...
Reviva Pharmaceuticals Holdings, Inc. Reports Third Quarter 2022 Financial Results and Recent Business Highlights
14. November 2022 16:05 ET
|
Reviva Pharmaceuticals
- Over 30% enrollment in ongoing global, pivotal Phase 3 RECOVER trial - - Topline data for Phase 3 RECOVER trial evaluating brilaroxazine for schizophrenia still expected mid-2023 - - $23.2...
Reviva Pharmaceuticals Announces Global Enrollment Update for Pivotal Phase 3 RECOVER Study Evaluating Brilaroxazine for Schizophrenia
31. Oktober 2022 08:00 ET
|
Reviva Pharmaceuticals
- Enrollment ongoing at multiple sites in the US and Europe; site initiation in Asia expected in November 2022 - - Enrollment on pace, with over 30% enrolled in the United States - - Topline data...
Reviva Pharmaceuticals to Present at the Lytham Partners Fall 2022 Investor Conference
26. September 2022 06:00 ET
|
Reviva Pharmaceuticals
CUPERTINO, Calif., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies...
Reviva Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference
07. September 2022 08:02 ET
|
Reviva Pharmaceuticals
CUPERTINO, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies...